SAREPTA THERAPEUTICS, INC. Proceeds from Lines of Credit
SAREPTA THERAPEUTICS, INC. (SRPT) reported Proceeds from Lines of Credit of $425.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromLinesOfCredit · last filed 2026-08-05
- SAREPTA THERAPEUTICS, INC. proceeds from lines of credit for the quarter ending 2026-06-30 was $175.00M.
- SAREPTA THERAPEUTICS, INC. proceeds from lines of credit for the quarter ending 2026-03-31 was $250.00M.
- SAREPTA THERAPEUTICS, INC. proceeds from lines of credit for the quarter ending 2025-06-30 was $0.00.
- SAREPTA THERAPEUTICS, INC. proceeds from lines of credit for the quarter ending 2025-03-31 was $0.00.
| Period end | Proceeds from Lines of Credit 3 month | Proceeds from Lines of Credit 6 month |
|---|---|---|
| 2026-06-30 | $175.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $425.00M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $250.00M 10-Q · filed 2026-05-06 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $0.00 10-Q · filed 2026-08-05 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |